Current Trials
ACTIVE CLINICAL STUDIES AT THE CRCNJ
To find out if you’re eligible, contact us at 973 850 4622 or click on the link to the trial of interest, complete the online form, and we will contact you.
Open
A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease (GREEN MEMORY)
SPONSOR: Eli Lilly
The purpose of this study is to evaluate the safety, tolerability and efficacy of GV-971 in mild to moderate Alzheimer's disease.
clinicaltrials.gov.
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
SPONSOR: Eli Lilly
The reason for this study is to see how safe and effective the study drug Donanemab is in participants with early Alzheimer's disease. clinicaltrials.gov.
For additional information, click here.
Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance
SPONSOR: vTv Therapeutics
This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease and impaired glucose tolerance. Patients will receive either azeliragon or placebo with a patient's participation lasting approximately 9 months (in Part 1) or 21 months (in Part 2). clinicaltrials.gov.
Memory Improvement Through Nicotine Dosing (MIND) Study
SPONSOR: University of Southern California
The purpose of the study is to see if daily transdermal nicotine is able to produce a significant cognitive, clinical and functional improvement in participants with MCI. Neuronal nicotinic receptors have long been known to play a critical role in memory function in preclinical studies, with nicotine improving attention, learning, and memory function. clinicaltrials.gov.
Active but closed to enrollment
Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease (GAIN Trial)
SPONSOR: Cortexyme Inc.
This is a randomized, double-blind, placebo-controlled study that will assess the efficacy, safety, and tolerability of 2 dose levels of COR388 in subjects with a clinical diagnosis of mild to moderate AD dementia. clinicaltrials.gov.
CLOSED TO ENROLLMENT
Multi-Center Study of Sensory Stimulation to Improve Brain Function (Overture)
SPONSOR: Cognito
The Overture Study is a randomized, controlled, single-blind multi-center clinical trial using the GammaSense Stimulation system to study safety, tolerability, and efficacy in people with mild to moderate cognitive impairment. clinicaltrials.gov
CLOSED TO ENROLLMENT
Phase 2 Study of BIIB092 in Participants With Early Alzheimer’s Disease (TANGO)
SPONSOR: BIOGEN
To evaluate the safety and tolerability of BIIB092 in participants with Mild Cognitive Impairment (MCI) due to Alzheimer’s disease (AD) or with mild AD. To evaluate the efficacy of multiple doses of BIIB092 in slowing cognitive and functional impairment in participants with MCI due to AD or with mild AD. To evaluate the immunogenicity of BIIB092 after multiple doses in participants with MCI due to AD or with mild AD. clinicaltrials.gov.
CLOSED TO ENROLLMENT
Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer’s Disease (AD)
SPONSOR: Roche
This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with early (prodromal to mild) AD. All participants must show evidence of beta-amyloid pathology. Eligible participants will be randomized 1:1 to receive either subcutaneous (SC) injection of gantenerumab or placebo. The primary efficacy assessment will be performed at the end of the double blind period at week 104. Participants will then be offered to enter into an open-label extension (OLE). Participants not willing to go to the OLE will participate in a long term follow-up period for up to 50 weeks after the last gantenerumab dose. clinicaltrials.gov.
CLOSED TO ENROLLMENT
A Study of LY3303560 in Participants With Early Symptomatic Alzheimer’s Disease
SPONSOR: Eli Lilly
The purpose of this study is to evaluate the safety and efficacy of a study drug that targets an abnormal protein in the brain found in people with Alzheimer's Disease (AD). clinicaltrials.gov.
CLOSED TO ENROLLMENT
Click here to make an appointment or call 973-850-4622 to learn more about how The CRCNJ can help.
